RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Zelira Therapeutics Stock

Zelira Therapeutics ROCE 2025

Zelira Therapeutics ROCE

1.11

Ticker

ZLD.AX

ISIN

AU000000ZLD1

WKN

A2AS5H

In 2025, Zelira Therapeutics's return on capital employed (ROCE) was 1.11, a -701.07% increase from the -0.18 ROCE in the previous year.

Zelira Therapeutics Aktienanalyse

What does Zelira Therapeutics do?

Zelira Therapeutics was founded in 2016 with its headquarters in Perth, Australia. The company focuses on the development, production, and marketing of medical cannabis to meet the needs of patients worldwide. The company's business model is based on producing medical cannabis specifically tailored to patients' needs. It works closely with doctors and patients to ensure its products are effective and meet patients' needs. Zelira Therapeutics operates in three main areas. The first is the development of products for treating pain and inflammation in chronic conditions such as multiple sclerosis, cancer, and epilepsy. The second area includes the development of products for treating sleep disorders. The third area is the development of products for treating mental disorders such as anxiety and depression. The company has developed a wide range of products, including oils, pills, sprays, and topical creams. An example of a product is the ZTL-101 oil, which was developed for treating pain and inflammation in patients with osteoarthritis. The oil contains a combination of CBD and THC. The company has also partnered with the University of Mississippi to research the use of medical cannabis for treating post-traumatic stress disorder (PTSD). The research is funded by the US government and aims to legitimize the use of medical cannabis for treating PTSD. Zelira Therapeutics has also formed partnerships with other companies and organizations to advance its research and development. In 2020, the company entered into an agreement with Emerald Health Therapeutics, a Canadian company specializing in the production of medical cannabis. The two companies will collaborate on developing products for treating sleep disorders. The company has also partnered with iCAN Israel-Cannabis, an Israel-based company specializing in the research and development of medical cannabis. The two companies are working together to develop new products and promote the use of medical cannabis in various countries. In addition to its partnerships, Zelira Therapeutics has established a strong presence in various international markets. It is currently operating in the US, Australia, New Zealand, and Germany, and is working to expand into other countries. Overall, Zelira Therapeutics is a company specializing in the development of medical cannabis for treating various conditions. It has a wide range of products and works closely with doctors and patients to ensure their effectiveness and meet patients' needs. With strong partnerships and a presence in various international markets, the company has a promising future. Zelira Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Zelira Therapeutics's Return on Capital Employed (ROCE)

Zelira Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Zelira Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Zelira Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Zelira Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Zelira Therapeutics stock

What is the ROCE (Return on Capital Employed) of Zelira Therapeutics this year?

The ROCE of Zelira Therapeutics is 1.11 undefined this year.

How has the ROCE (Return on Capital Employed) of Zelira Therapeutics developed compared to the previous year?

The ROCE of Zelira Therapeutics has increased by -701.07% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Zelira Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Zelira Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Zelira Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Zelira Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Zelira Therapeutics impact the company?

An increase in the ROCE of Zelira Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Zelira Therapeutics affect the company?

A decrease in ROCE of Zelira Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Zelira Therapeutics?

Some factors that can affect Zelira Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Zelira Therapeutics so important for investors?

The ROCE of Zelira Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Zelira Therapeutics take to improve the ROCE?

To improve the ROCE, Zelira Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Zelira Therapeutics pay?

Over the past 12 months, Zelira Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zelira Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Zelira Therapeutics?

The current dividend yield of Zelira Therapeutics is .

When does Zelira Therapeutics pay dividends?

Zelira Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zelira Therapeutics?

Zelira Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Zelira Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zelira Therapeutics located?

Zelira Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zelira Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zelira Therapeutics from 6/27/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 6/27/2025.

When did Zelira Therapeutics pay the last dividend?

The last dividend was paid out on 6/27/2025.

What was the dividend of Zelira Therapeutics in the year 2024?

In the year 2024, Zelira Therapeutics distributed 0 AUD as dividends.

In which currency does Zelira Therapeutics pay out the dividend?

The dividends of Zelira Therapeutics are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Zelira Therapeutics

Our stock analysis for Zelira Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zelira Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.